Crinetics Pharmaceuticals (CRNX) FCF Margin (2017 - 2026)
Crinetics Pharmaceuticals (CRNX) posted quarterly FCF Margin of 1166.08% for Q1 2026, up 2340899.0% year-over-year from N/an in Q1 2025, and up 22.94% quarter-over-quarter from 1513.28% in Q4 2025.
Powered by 
Analysis
Crinetics Pharmaceuticals (CRNX) FCF Margin (2017 - 2026) Analysis & Trends
Crinetics Pharmaceuticals' FCF Margin history runs 10 years deep, the most recent figure standing at 1166.08% for Q1 2026.
- In Q1 2026, FCF Margin rose 2340899.0% year-over-year to 1166.08%; the TTM figure through Mar 2026 stood at 2295.43% (up 3304220.0% YoY), while the FY2025 annual figure was 4915.68%, up 1760963.0% from the prior year.
- FCF Margin for Q1 2026 stood at 1166.08%, up from 1513.28% in the prior quarter.
- The five-year high for FCF Margin was 435.32% in Q1 2022, with the low at 74359.44% in Q3 2025.
- The 5-year median for FCF Margin is 7419.2% (2022), against an average of 12070.13%.
- The sharpest annual moves came in 2025 and 2026: FCF Margin tumbled 1610819 bps in 2025, then surged 2340899 bps in 2026.
- Crinetics Pharmaceuticals' FCF Margin stood at 4770.8% in 2022, then tumbled by 153 bps to 12059.83% in 2023, then rose by 3 bps to 11694.24% in 2024, then soared by 87 bps to 1513.28% in 2025, then grew by 23 bps to 1166.08% in 2026.
- Business Quant data shows CRNX's FCF Margin at 1166.08% in Q1 2026, 1513.28% in Q4 2025, and 74359.44% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Crinetics Pharmaceuticals | 8.99 Bn | 8.99 Bn | 24.96 Mn | -377.08% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -377.08% |
| Mar 31, 2026 | -1,169.40% |
| Dec 31, 2025 | -1,515.32% |
| Sep 30, 2025 | -78,028.67% |
| Jun 30, 2025 | -8,637.54% |
| Mar 31, 2025 | -24,845.15% |
| Jun 30, 2024 | -12,180.20% |
| Mar 31, 2024 | -8,466.88% |
| Sep 30, 2023 | -12,959.25% |
| Jun 30, 2023 | -4,651.32% |
| Mar 31, 2023 | -1,521.13% |
| Dec 31, 2022 | -5,004.37% |
| Sep 30, 2022 | -8,550.44% |
| Jun 30, 2022 | -6,512.30% |
| Mar 31, 2022 | -435.32% |
| Dec 31, 2021 | -2,125.88% |
| Mar 31, 2020 | -17,309.86% |
| Dec 31, 2019 | -4,197.82% |
| Sep 30, 2019 | -2,694.46% |
| Mar 31, 2019 | -1,952.86% |